RESULTS Act
Summary
The RESULTS Act (HR5269) is an early-stage bill aiming to stabilize Medicare reimbursement for clinical diagnostic lab tests by improving data accuracy. It has 77 cosponsors and a companion bill in the Senate but remains in committee with no near-term market impact. Real market data shows LH at $259 and DGX at $190.19, both down ~3% over 30 days, reflecting sector headwinds unrelated to this procedural legislation.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR5269 (RESULTS Act) is an early-stage procedural bill with no funding attached and no near-the-month market impact.
- 2.Real market data shows LH at $259 and DGX at $190.19; both have declined ~3% over 30 days from sector trends, not this legislation.
- 3.The bill has 77 cosponsors and a Senate companion, indicating potential future momentum, but it is not yet investable for retail investors.
Market Implications
The RESULTS Act has zero actionable market implications at this time. Labcorp ($LH) and Quest Diagnostics ($DGX) are the most directly exposed tickers, but with the bill only referred to committee and no fiscal impact estimate, there is no basis for trade positioning. Both stocks have been declining over the past month (DGX -2.95%, LH -2.93%) due to broader healthcare sector dynamics, not this legislation. Investors should monitor committee activity — particularly a Ways and Means markup or CBO scoring — before treating this as a market-moving event.
Full Analysis
On September 10, 2025, Representative Richard Hudson (R-NC) introduced H.R. 5269, the RESULTS Act, in the 119th Congress. The bill was referred to both the Energy and Commerce and Ways and Means Committees. It is in the earliest legislative stage — no hearings, markup, or floor votes have occurred. The bill's purpose is to amend the Social Security Act to improve data collection for the private payor-based fee schedule used to set Medicare payment rates for clinical diagnostic lab tests, aiming to provide long-term rate stability.
The bill does not authorize or appropriate any specific funding amount. It modifies data submission requirements and data source standards — a regulatory and data standardization bill, not a spending bill. Actual Medicare payment rates would still be set through the existing administrative process using data collected under this updated framework; no direct financial transfer occurs from this legislation.
The primary affected entities are publicly traded clinical lab companies Labcorp ($LH) and Quest Diagnostics ($DGX), as Medicare lab test revenue is material to both. However, at this early stage — bill text still in committee, no CBO score, no budget impact — the market impact is negligible. The bill's 77 bipartisan cosponsors and companion Senate bill (S. 2761) indicate broad support, but the legislative path requires full committee approval, House passage, Senate passage, and presidential action — a multi-year timeline at best.
Real market data from Yahoo Finance shows LH at $259 (52-week range: $235.81–$293.72) with a 30-day decline of -2.93%. DGX is at $190.19 (52-week range: $164.65–$213.50) with a 30-day decline of -2.95%. Both stocks have weakened in the last week (LH -1.82%, DGX -3.1%), consistent with broader market conditions rather than this specific bill.
Any material market impact from the RESULTS Act requires significant advancement through the legislative process. The earliest actionable milestone would be a committee markup or CBO score showing a net effect on Medicare spending or lab industry revenues. As of today, April 30, 2026, the bill remains in procedural limbo.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
data collection and accuracy improvement for private payor-based fee schedule payment rates under Medicare for clinical diagnostic laboratory tests
Who must act
clinical diagnostic laboratories, including Labcorp, that submit private payor data to the Secretary of HHS for Medicare payment rate determination
What happens
the bill modifies data collection requirements for widely available non-advanced diagnostic lab tests, potentially altering the data inputs that determine the weighted median private payor rate used to set Medicare payment for these tests
Stock impact
Labcorp generates a significant portion of its revenue from clinical lab testing, a portion of which is reimbursed by Medicare under the fee schedule this bill adjusts; any change in rate calculation methodology could stabilize or shift Labcorp's Medicare reimbursement levels, but the specific financial impact cannot be quantified without knowing the final data source or rate recalculation parameters
What the bill does
data collection and accuracy improvement for private payor-based fee schedule payment rates under Medicare for clinical diagnostic laboratory tests
Who must act
clinical diagnostic laboratories, including Quest Diagnostics, that submit private payor data to the Secretary of HHS for Medicare payment rate determination
What happens
the bill modifies data collection requirements for widely available non-advanced diagnostic lab tests, potentially altering the data inputs that determine the weighted median private payor rate used to set Medicare payment for these tests
Stock impact
Quest Diagnostics is the largest standalone clinical lab company in the US and a significant Medicare fee-for-service provider; changes to the data collection accuracy and feasibility could reduce administrative burden or alter reimbursement rates, but the net revenue impact is unknown at this early legislative stage
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SUPPORT for Patients and Communities Reauthorization Act of 2025
ASAP Act
CHOICE for Veterans Act of 2025
Supporting Healthy Moms and Babies Act
Reducing Hereditary Cancer Act
Thyroid Disease CARE Act of 2025
Increasing Access to Lung Cancer Screening Act
Access to Breast Cancer Diagnosis Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →